|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 prophylaxis (excluding children) meta-analysis
|RCT||cilgavimab and tixagevimab (Evusheld)||placebo||COVID-19 prophylaxis (excluding children)||low||3460/1737||conclusif|
|1 study excluded by filtering options (0 RCT / 1 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).